0Y5F Stock Overview
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Endo International plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0006 |
| 52 Week High | US$0.069 |
| 52 Week Low | US$0.0003 |
| Beta | 0.80 |
| 1 Month Change | 20.00% |
| 3 Month Change | -40.00% |
| 1 Year Change | -99.08% |
| 3 Year Change | -99.99% |
| 5 Year Change | -99.99% |
| Change since IPO | -99.99% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0Y5F | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | -50.0% | 3.3% | 2.7% |
| 1Y | -99.1% | -3.7% | 0.3% |
Return vs Industry: 0Y5F underperformed the UK Pharmaceuticals industry which returned -3.7% over the past year.
Return vs Market: 0Y5F underperformed the UK Market which returned 0.3% over the past year.
Price Volatility
| 0Y5F volatility | |
|---|---|
| 0Y5F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 8.4% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0Y5F's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 0Y5F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1920 | 2,931 | Blaise Coleman | www.endo.com |
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. It operates in four segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals. The company offers branded pharmaceuticals, including XIAFLEX to treat adult patients with Dupuytren’s contracture and Peyronie’s disease; SUPPRELIN LA to treat central precocious puberty in children; AVEED to treat hypogonadism; NASCOBAL nasal spray to treat vitamin B12 deficiency; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET for pain management; TESTOPEL, an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; and EDEX to treat erectile dysfunction, as well as opioid products to treat pain associated with post-herpetic neuralgia.
Endo International plc Fundamentals Summary
| 0Y5F fundamental statistics | |
|---|---|
| Market cap | US$141.13k |
| Earnings (TTM) | -US$2.45b |
| Revenue (TTM) | US$2.01b |
0.0x
P/S Ratio0.0x
P/E RatioIs 0Y5F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0Y5F income statement (TTM) | |
|---|---|
| Revenue | US$2.01b |
| Cost of Revenue | US$941.90m |
| Gross Profit | US$1.07b |
| Other Expenses | US$3.52b |
| Earnings | -US$2.45b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -10.41 |
| Gross Margin | 53.17% |
| Net Profit Margin | -121.69% |
| Debt/Equity Ratio | -123.5% |
How did 0Y5F perform over the long term?
See historical performance and comparison